Taiwan-based digital health startup Health2Sync and French multinational pharmaceutical company Sanofi have signed another partnership to bring digital solutions for insulin management to Japan. Copy.
WHAT IT’S ABOUT
According to a press statement, both companies will jointly develop digital features on insulin in Japan, including connecting caps for insulin alerts and titrations.
Health2Sync has a mobile health app currently used by about 290,000 patients in Japan.
WHY IT IMPORTANT
Recently research of the Japan Diabetes Clinical Data Management Study Group found that mean HbA1c levels tended to increase in people living with diabetes. It also notes that Japanese patients are receiving an average of 14.8 units of basal insulin at 7.8% HbA1c, suggesting that basal insulin doses can be further optimized through further approaches. appropriate approach. However, constantly recording blood glucose levels can be difficult for diabetics, who are already struggling to control their disease in an unstable environment.
Health2Sync and Sanofi claim their digital solutions will help improve insulin management among healthcare providers and diabetes patients in Japan.
This latest partnership “underlines the companies’ ambition to realize more comprehensive chronic disease management through digital solutions,” a press release reads.
TREND TO BIGGER
Health2Sync and Sanofi collaborate for the first time in 2020 in one digital health plan has provided digital solutions to over 200 clinics and over 10,000 insulin patients across Asia to date.
Last year, companies expand their partnership to jointly develop an automated digital insulin management solution with titration algorithms, which are currently being studied for their therapeutic effects.
Both companies still plan to expand their partnership in bringing digital treatment solutions to patients and healthcare professionals in Japan and other markets.
